- Roche Canada announced that Itovebi has been added to Québec’s RAMQ List of Medications for eligible patients with advanced HR-positive, HER2-negative breast cancer with a PIK3CA mutation, effective June 25, 2026.
- The listing follows unanimous therapeutic value recognition from INESSS and successful pCPA negotiations. It is based on INAVO120 data, where Itovebi more than doubled median progression-free survival to 15 months vs. 7.3 months.
- Itovebi, combined with palbociclib and fulvestrant, also delivered a statistically significant overall survival benefit, reducing the risk of death by 33% in patients with endocrine-resistant, PIK3CA-mutated advanced breast cancer.
- Roche said it will continue working with provincial and territorial drug plans to expand public access nationwide, as HR-positive breast cancer accounts for ~70% of all breast cancer cases in Canada.
Takeaways:
Itovebi’s addition to Québec’s RAMQ list means eligible patients with advanced HR‑positive, HER2‑negative, PIK3CA‑mutated breast cancer can now access a targeted pill that, in the INAVO120 trial, more than doubled time before the cancer worsened (15 vs 7.3 months) and lowered the risk of death by about one‑third when added to standard therapy. For patients and oncologists, this expands options after endocrine resistance, supports mutation‑guided treatment, and because HR‑positive disease is ~70% of breast cancers, could set the stage for broader provincial coverage as Roche continues negotiations across Canada.
Source: CA Newswire
